News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
CeNes Pharmaceuticals (U.S.) Starts Recruitment for Phase II trial of CNS 5161 for Cancer Pain
September 12, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Thomson Financial) - CeNeS Pharmaceuticals PLC said it has started recruitment for a Phase II study of the potential new pain drug CNS 5161, which is being developed under a co-development deal with the ERGOMED Group.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
MORE ON THIS TOPIC
Clinical research
BridgeBio Shares Pop Again as Phase III Thyroid Drug Exceeds Investor Expectations
October 29, 2025
·
3 min read
·
Annalee Armstrong
Immunology and inflammation
Aldeyra Cans RASP Asset, Brings Forward Two Others in Pipeline Shakeup
October 29, 2025
·
2 min read
·
Tristan Manalac
Podcast
Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More
October 29, 2025
·
1 min read
·
Heather McKenzie
Autoimmune disease
Cabaletta’s CAR T Therapy Spurs Remissions in Small Lupus Trial
October 28, 2025
·
2 min read
·
Tristan Manalac
